2 results
Approved WMOCompleted
In patients with symptomatic New York Heart Association (NYHA) Class II/III/IV dilated cardiomyopathy (DCM) in which mutations in the gene encoding the lamin A/C protein (LMNA) have been implicated:Primary Objective:* NYHA Class II/III patients only…
Approved WMOCompleted
Rationale:The aim of this study is to investigate the pharmacodynamics (PD), pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20)…